Evive Biotech is a global biologics company focused on oncology, inflammatory and metabolic diseases. As the first biopharmaceutical company to build a platform bringing innovative therapies from China to the world, we adopt a holistic approach to drug development, combining exceptional research and commercialization capabilities with our world-class in-house regulatory expertise and extensive international management experience.
Revolutionary remedies for a healthy and happy world.
Developing innovative medicines for patients worldwide.
What’s Going On
Our innovative assets have recently achieved significant milestones, including the completion of F-627's global Phase III clinical trials, which met its primary and secondary endpoints, the BLA submission of F-627 to the US FDA, and the receipt of orphan drug designation from the US FDA for F-652. We are engaging with potential partners and the broader scientific community to share our successes and to ensure broad access to treatment options for patients.
Evive Biotech Announces the Appointment of Dr. Simon Li as Executive VP, Chief Medical Officer
Evive Biotech Announces the Appointment of Dr. Jing Wang as VP, Clinical Pharmacology
Evive Biotech’s Ryzneuta™ Marketing Authorization Application Accepted for Review by European Medicines Agency
Evive Biotech Announces Recent Appointments: VP of Biometrics and VP of Clinical Operations
Evive Biotech Announces IND Approval by the NMPA for a Phase II Clinical Study of F-652 in Patients with ACLF
Evive Biotech Announces the Appointment of Dr. Lichuan Liu as Senior VP, Global Head of Clinical and Translational Science